ArticleCureus2025
A Fatal Case of Cardiac Sarcoidosis Presenting as Refractory Ascites.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a multisystem granulomatous disease with variable clinical presentations, most commonly affecting the lungs. Cardiac sarcoidosis (CS), though rare, is a serious complication that can lead to restrictive cardiomyopathy and carries a poor prognosis. We report the case of a 44-year-old male patient who presented with worsening ascites, fatigue, orthopnea, and peripheral edema. Initial workup revealed transudative ascites and new-onset severe heart failure, with echocardiography showing an ejection fraction of 15%-20%, bi-atrial enlargement, left ventricular hypertrophy, and grade 3 diastolic dysfunction. Cardiac catheterization confirmed non-ischemic cardiomyopathy. Imaging showed pulmonary and mediastinal lymphadenopathy and ground-glass opacities. Due to the patient's instability, a biopsy was deferred, and a myocardial fluorodeoxyglucose-18 positron emission tomography (FDG-PET) scan was performed, demonstrating diffuse hypermetabolic activity consistent with active CS. Despite immunosuppressive therapy with prednisone, methotrexate, hydroxychloroquine, and folate, the patient deteriorated and succumbed to fatal arrhythmias and advanced conduction abnormalities. This case highlights the diagnostic utility of FDG-PET in unstable patients and underscores the importance of considering CS in patients with unexplained heart failure and transudative ascites. Early recognition and consideration for cardiac transplant are critical in improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.